These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 27876386)
1. Future perspectives in the medical treatment of benign prostatic hyperplasia. Alcántara Montero A Actas Urol Esp; 2017 Jun; 41(5):343-344. PubMed ID: 27876386 [No Abstract] [Full Text] [Related]
2. Current management and future trends in benign prostatic hyperplasia (BPH). Fitzpatrick JM Ir Med J; 1997 Nov; 90(7):256, 258. PubMed ID: 10036815 [No Abstract] [Full Text] [Related]
3. [Medical therapy of benign prostatic hyperplasia]. Altarac S Lijec Vjesn; 2005; 127(11-12):316-23. PubMed ID: 16583940 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological treatment of benign prostatic hyperplasia, current options and future perspectives. Hansen BJ Scand J Urol Nephrol Suppl; 1996; 180():1-55. PubMed ID: 8936639 [No Abstract] [Full Text] [Related]
9. Perspectives on the management of benign prostatic hyperplasia. Janknegt RA Scand J Urol Nephrol Suppl; 1995; 168():35-36. PubMed ID: 7541550 [No Abstract] [Full Text] [Related]
10. Pharmacotherapy for benign prostatic hyperplasia. Narayan P; Indudhara R West J Med; 1994 Nov; 161(5):495-506. PubMed ID: 7528957 [TBL] [Abstract][Full Text] [Related]
11. Medical treatment of benign prostatic hyperplasia. Connolly SS; Fitzpatrick JM Postgrad Med J; 2007 Feb; 83(976):73-8. PubMed ID: 17308208 [TBL] [Abstract][Full Text] [Related]
12. Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future. Clarke DE Br J Urol; 1998 Jul; 82(1):167. PubMed ID: 9698692 [No Abstract] [Full Text] [Related]
13. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists. Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746 [TBL] [Abstract][Full Text] [Related]
14. Medical treatment of benign prostatic hyperplasia. Lancet; 1988 May; 1(8594):1083-4. PubMed ID: 2452939 [No Abstract] [Full Text] [Related]
15. Advances in the medical management of benign prostatic hyperplasia. Jewett MA; Klotz LH; CMAJ; 2007 Jun; 176(13):1850-1. PubMed ID: 17576985 [No Abstract] [Full Text] [Related]
16. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms. Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690 [TBL] [Abstract][Full Text] [Related]
17. Optimising the medical management of benign prostatic hyperplasia. McDermott T Br J Clin Pract; 1997 Mar; 51(2):116-8. PubMed ID: 9158256 [TBL] [Abstract][Full Text] [Related]
18. Estrogen suppression as a pharmacotherapeutic strategy in the medical treatment of benign prostatic hyperplasia: evidence for its efficacy from studies with mepartricin. Boehm S; Nirnberger G; Ferrari P Wien Klin Wochenschr; 1998 Dec; 110(23):817-23. PubMed ID: 10025034 [TBL] [Abstract][Full Text] [Related]
20. Evaluation and validation of the core lower urinary tract symptom score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: effects of the α1-adrenoreceptor antagonist silodosin. Ito H; Sano F; Ogawa T; Yao M Int J Urol; 2014 Jan; 21(1):108-12. PubMed ID: 23662900 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]